Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...
Hims & Hers Health (NYSE:HIMS) Craters With Weight Loss Drug Issues
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Hims & Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
Why Hims & Hers Stock Has Further to Fall: Heard on the Street
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Hims & Hers Health: Focus On The Future, Not GLP-1s
Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.
Hims & Hers Health 4Q Revenue Surges on Boost From Weight-Loss Treatments
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...